Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata

This study investigates the efficacy and safety of ritlecitinib, a JAK3/TEC inhibitor, in patients with severe alopecia areata (AA) inadequate or no response to baricitinib, a JAK1/2 inhibitor. Our results indicate that treatment with ritlecitinib not only leads to significant improvements in hair regrowth and quality of life but also positively impacts the psychological well-being of patients with severe AA. our study highlights an inadequate or no response to one JAKi does not necessarily predict failure with another.